H1N1pdm09 Adjuvanted Vaccination in HIV-Infected Adults: A Randomized Trial of Two Single versus Two Double Doses

Background Since human immunodeficiency virus (HIV)-infected individuals are at increased risk of severe disease from pandemic influenza A (H1N1pdm09), vaccination was recommended as a prevention strategy. The aim of the present study was to evaluate the safety, immunogenicity and persistence of the immune response after vaccination against pandemic influenza A (H1N1pdm09) with an adjuvanted vaccine in human immunodeficiency virus (HIV)-infected adults using two single and two double doses. Methodology/Principal Findings Open label, randomized trial to evaluate the immune response following H1N1pdm09 vaccination in HIV-infected participants compared to HIV-negative controls (NCT01155037). HIV-infected participants were randomized to receive 2 single (3.75 µg hemagglutinin) or 2 double (7.5 µg hemagglutinin) doses of the vaccine, 21 days apart. Controls received one dose of the vaccine. The primary endpoint was seroconversion as measured by hemagglutination inhibition assay. Two hundred fifty six HIV-infected participants (129 and 127 randomized to single and double doses, respectively) and 71 HIV-negative controls were enrolled. Among HIV-infected participants, seroconversion increased from 46.7% and 51.7% after the first dose to 77.2% and 83.8% after the second dose of the vaccine using single and double doses, respectively. Participants aged >40 years showed higher seroconversion compared to younger participants. Seroconversion among HIV-infected women and those with nadir CD4<200 cells/mm3 was significantly higher with double doses. Persistence of protective antibodies six months after vaccination was achieved by 80% and 89.9% of the HIV-infected participants who received single and double doses, respectively. Conclusions/Significance Our results support the recommendation of two double doses of adjuvanted H1N1pdm09 vaccine for HIV-infected individuals, particularly women, and those aged >40 years or with nadir CD4<200 cells/mm3, to achieve antibody levels that are both higher and more sustained. Trial Registration ClinicalTrials.gov NCT01155037

[1]  A. Klimov,et al.  Influenza: Propagation, Quantification, and Storage , 2013, Current protocols in microbiology.

[2]  F. Raffi,et al.  Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. , 2011, The Journal of infectious diseases.

[3]  L. Eberly,et al.  Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. , 2011, Vaccine.

[4]  G. Rimmelzwaan,et al.  Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination , 2011, PloS one.

[5]  I. Frank,et al.  Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals , 2010, AIDS.

[6]  M. Bickel,et al.  Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients , 2010, AIDS (London).

[7]  Michael Shaw,et al.  Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. , 2010, The New England journal of medicine.

[8]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[9]  N. Andrews,et al.  Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study , 2010, The Lancet.

[10]  R. Rappuoli,et al.  H1N1: Can a Pandemic Cycle Be Broken? , 2010, Science Translational Medicine.

[11]  Chih-Jen Wei,et al.  Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design , 2010, Science Translational Medicine.

[12]  C. Melloni,et al.  Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention , 2010, Current Cardiovascular Risk Reports.

[13]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[14]  G. Penna,et al.  Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI). , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  E. Smit,et al.  Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK , 2009, The Lancet.

[16]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[17]  R. Jagsi,et al.  Under‐representation of women in high‐impact published clinical cancer research , 2009, Cancer.

[18]  T. Vesikari,et al.  Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant , 2009, The Pediatric infectious disease journal.

[19]  Derek Gatherer,et al.  The 2009 H1N1 influenza outbreak in its historical context. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  Yi Guan,et al.  Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[21]  H. Furrer,et al.  Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Zambon,et al.  Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine , 2009, Proceedings of the National Academy of Sciences.

[23]  G. Rimmelzwaan,et al.  Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. , 2009, Vaccine.

[24]  G. Leroux-Roels,et al.  Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. , 2008, Vaccine.

[25]  R. Couch,et al.  Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. , 2008, The Journal of infectious diseases.

[26]  F. de Looze,et al.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. , 2008, The Journal of infectious diseases.

[27]  R. Walker,et al.  Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. , 2008, Vaccine.

[28]  E. Pariani,et al.  Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.

[29]  J. Brownstein,et al.  Efficacy of influenza vaccination in HIV‐positive patients: a systematic review and meta‐analysis , 2008, HIV medicine.

[30]  R. Compans,et al.  Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal Immunization , 2007, Journal of Virology.

[31]  G. Boivin,et al.  Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R. Couch,et al.  Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  A. Adimora,et al.  Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis , 2006, BMC infectious diseases.

[34]  R. Couch,et al.  Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. , 2006, Archives of internal medicine.

[35]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[36]  D. Folgueira,et al.  Respiratory Virus Infections in Children With Cancer or HIV Infection , 2006, Journal of pediatric hematology/oncology.

[37]  S. Weissman,et al.  Response to hepatitis A vaccine in HIV‐positive patients 1 , 2006, Journal of viral hepatitis.

[38]  N. Shire,et al.  Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. , 2006, Vaccine.

[39]  Philimon N. Gona,et al.  Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. , 2006, The Journal of infectious diseases.

[40]  Louette R. Johnson Lutjens.  Research , 2006 .

[41]  J. Guest,et al.  Response to hepatitis A vaccine in HIV patients in the HAART era , 2005, AIDS.

[42]  W. Powderly,et al.  Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  S. Oka,et al.  Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.

[44]  A. Pontiroli,et al.  Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. , 2005, AIDS research and human retroviruses.

[45]  E. Tanzi,et al.  Safety and immunogenicity of influenza vaccination in individuals infected with HIV. , 2002, Vaccine.

[46]  S. Madhi,et al.  Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection , 2002, The Pediatric infectious disease journal.

[47]  E. Tanzi,et al.  Influenza vaccination of HIV‐1‐positive and hiv‐1‐negative former intravenous drug users , 2001, Journal of medical virology.

[48]  M. Rosen,et al.  Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. , 2001, American journal of respiratory and critical care medicine.

[49]  C. Bridges,et al.  Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  W. Blackwelder,et al.  Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. , 2001, Vaccine.

[51]  David J Harris,et al.  Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. , 2000, The New England journal of medicine.

[52]  J. Oxford,et al.  Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology , 2000, Reviews in medical virology.

[53]  Lihan K. Yan,et al.  Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. , 2000, The Journal of infectious diseases.

[54]  J. Lang,et al.  Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. , 2000, Vaccine.

[55]  S. Tasker,et al.  Efficacy of Influenza Vaccination in HIV-Infected Persons , 1999, Annals of Internal Medicine.

[56]  M. Peiris,et al.  Human infection with influenza H9N2 , 1999, The Lancet.

[57]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[58]  A. Osterhaus,et al.  Restored humoral immune response to influenza vaccination in HIV‐infected adults treated with highly active antiretroviral therapy , 1998, AIDS.

[59]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[60]  N. Cox,et al.  Influenza pandemic preparedness plan for the United States. , 1997, The Journal of infectious diseases.

[61]  H. Kessler,et al.  Immunologic and virologic evaluation after influenza vaccination of HIV‐1‐infected patients , 1997, AIDS.

[62]  M. Rosen,et al.  Pulmonary complications of HIV infection , 2008, Respirology.

[63]  R. Couch,et al.  Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly , 1996, Clinical and diagnostic laboratory immunology.

[64]  T. Elbeik,et al.  Activation of virus replication after vaccination of HIV-1-infected individuals , 1995, The Journal of experimental medicine.

[65]  R. Couch,et al.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults , 1994, Journal of clinical microbiology.

[66]  J. D. de Jong,et al.  Antibody response to influenza, tetanus and pneumococcal vaccines in HIV‐seropositive individuals in relation to the number of CD4+ lymphocytes , 1994, AIDS.

[67]  K. Edwards,et al.  Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. , 1994, The Pediatric infectious disease journal.

[68]  I. Keet,et al.  Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. , 1992, AIDS.

[69]  M. Bruguera,et al.  Impaired Response to Recombinant Hepatitis B Vaccine in HIV‐Infected Persons , 1992, Journal of clinical gastroenterology.

[70]  J. Rodicio,et al.  Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. , 1990, Vaccine.

[71]  J. Margolick,et al.  The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. , 1989, JAMA.

[72]  B. Polk,et al.  The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. , 1988, Annals of internal medicine.

[73]  C. Denning,et al.  Immunization of Elderly People with High Doses of Influenza Vaccine , 1988, Journal of the American Geriatrics Society.

[74]  M. Ragni,et al.  Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. , 1987, The Journal of laboratory and clinical medicine.

[75]  H. Matzkin,et al.  Accidental tenfold overdose of influenza vaccine: a clinical and serological study. , 1984, Israel journal of medical sciences.

[76]  F. Ennis,et al.  Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. , 1977, The Journal of infectious diseases.

[77]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[78]  G. Jackson,et al.  A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. , 1972, The Journal of infectious diseases.

[79]  J. Haldane,et al.  On a method of estimating frequencies. , 1945, Biometrika.

[80]  R. Dolin.  Editorial commentary: Perspectives on the role of immunization against influenza in HIV-infected patients. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[81]  M. Bickel,et al.  Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  L. Eberly,et al.  Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[84]  T. Popović,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009, MMWR. Morbidity and mortality weekly report.

[85]  P. N. Silva,et al.  Sampling design for the World Health Survey in Brazil. , 2005, Cadernos de Saúde Pública.

[86]  F. Ruben,et al.  Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine , 2005, Archives of Virology.

[87]  Inactivated influenza vaccine: what you need to know. , 2005, South Dakota journal of medicine.

[88]  Keiji Fukuda,et al.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[89]  M. Castrucci,et al.  Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. , 1997, Vaccine.

[90]  K. Sankar,et al.  Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. , 1994, AIDS.

[91]  W. Roper,et al.  Prevention and control of influenza: Part I, Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1994, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[92]  W. Beyer,et al.  Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. , 1993, Vaccine.

[93]  R B Couch,et al.  Immunity to influenza in man. , 1983, Annual review of microbiology.